Gray peptide vendors embrace stablecoins as safety fears deepen

Crypto has become a key payment rail for a fast-growing gray-market peptide trade, according to a new Chainalysis report.

• Chainalysis said gray-market peptide sales topped a $100 million annual run rate as buyers increasingly used crypto payments online.
• The report said first-quarter peptide sales reached $32 million, rising 159% from $12 million in the previous quarter.
• Chainalysis found that larger peptide vendors relied more on stablecoins to reduce exposure to Bitcoin’s sharp price swings.

Chainalysis said Thursday that off-label peptide sales have climbed past a $100 million annual run rate, as online wellness trends and demand for cheaper compounds push buyers toward overseas suppliers. The blockchain analytics firm said first-quarter sales in 2026 reached $32 million, up 159% from $12 million in the prior quarter.

The report linked the surge to rising public interest in peptides, which are protein building blocks used across health, fitness, and wellness markets. Chainalysis said the success of GLP-1 drugs such as Ozempic and Wegovy helped bring related products into mainstream online discussion, even as many buyers turned to unregulated alternatives.

Crypto becomes payment backbone

According to Chainalysis, traditional banks and card processors often restrict transactions tied to prescription-grade compounds and unregulated substances. As a result, the firm said many vendors have adopted cryptocurrency to handle payments outside normal financial channels.

Chainalysis described the peptide trade as a “gray market” served by overseas suppliers that sell raw and unbranded products directly to consumers. The firm said Chinese chemical manufacturers now account for much of the supply, partly because some sellers face limits in traditional banking systems.

In its report, Chainalysis said top vendors have developed a more organized approach to crypto payments. The firm found that suppliers often use bitcoin and stablecoins, while larger vendors show a stronger preference for stablecoins.

You might also like: JPMorgan warns CLARITY Act window may be closing fast

Stablecoins dominate larger orders

Among vendors receiving average deposits of $1,000 or more, Chainalysis said stablecoins made up most of the payment mix. The firm said this pattern may help sellers reduce exposure to Bitcoin’s price swings when handling larger supply orders.

The report also compared the peptide market with other research-chemical networks that have used crypto for online sales. Chainalysis said some suppliers connected to fentanyl precursor sales appear to have moved into peptides or added them to existing operations.

One example cited by Chainalysis was Shanghai Sigma Audley. The firm said the supplier, which it linked to suspected transnational drug networks, had received at least $1 million in bitcoin and $3.59 million in stablecoins from fentanyl precursor sales before expanding into peptides.

You might also like: Russia targets 17-year-old Browder over A7A5 crypto findings

Testing spend falls per buyer

Chainalysis also raised concerns about product safety. The firm said many wallets that bought peptides from China previously sent funds to Janoshik, a Czech company that provides independent chemical purity testing.

However, Chainalysis said testing spend per buyer has dropped sharply as the market has grown. The report estimated that average testing spend fell 88% to about $8 per buyer, even though Janoshik is testing more products overall because the number of buyers has increased.

The report said the peptide sector often reaches people with limited experience in both cryptocurrency and unregulated pharmaceuticals. Chainalysis said this creates added risk for buyers who may not understand product quality concerns, payment traceability, or the legal limits around these substances.

Read more: Hyperliquid price pulls back from ATH as Arthur Hayes exits HYPE, can bulls hold above $60?